Tag : CTLA4

Latest News

OncoImmune Announces Approval of IND Application for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA-4 Recycling for Better Safety and Efficacy

Newsemia
ROCKVILLE, Md.–(BUSINESS WIRE)–OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has been approved by...
Latest News

Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis

Newsemia
Serwas, NK; Hoeger, B; Ardy, RC; Stulz, SV; Sui, Z; Memaran, N; Meeths, M; … Boztug, K; + view all Serwas, NK; Hoeger, B; Ardy,...
Latest News

Addition of CTLA4 targeted therapy to PD-1 targeted therapy may benefit patients with ovarian cancer

Newsemia
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy